Table 1.

Demographic and clinical characteristics of participants

All Participants (n=836,060)Baseline eGFR (ml/min per 1.73 m2)
15–59.9 (n=47,092)60–89.9 (n=351,849)≥90 (n=437,119)
Agea (yr)49.4 (14.8)70.5 (11.5)55.6 (12.9)42.1 (11.8)
LDL-Ca (mmol/L)3.1 (0.9)3.1 (0.9)3.2 (0.9)3.0 (0.9)
LDL-C (mmol/L)
 <2.628312432
 2.6–3.3936343536
 3.4–4.0923222521
 4.1–4.891010129
 ≥4.93332
Women50554752
Aboriginal status1112
Socioeconomic status
 Low94710
 Social assistance2223
Diabetes82297
Hypertension23662914
eGFR (ml/min per 1.73 m2)b91 (78, 103)53 (45, 57)79 (72, 85)102 (96, 110)
Proteinuria
 None91789192
 Mild81687
 Heavy1611
Charlson comorbidities
 Cancer3732
 CVD2721
 CHF1810
 Chronic lung disease12171211
 Dementia0200
 Metastatic solid tumor0100
 Myocardial infarction2721
 Mild liver disease1111
 Moderate/severe liver disease0000
 Paraplegia0100
 Peptic ulcer disease2322
 Peripheral vascular disease1510
 Rheumatic disease1211
Medication usec
 Statin1729188
 ACE inhibitor or ARB23462310
β-blocker1023104
 Fibrate or ezetimibe2621
  • Data expressed as percent except where noted. Totals do not always add to 100% because of rounding. Proteinuria defined as none (ACR<30 mg/g or urine dipstick negative), mild (ACR=30–300 mg/g or urine dipstick trace or 1+), or heavy (ACR>300 mg/g or urine dipstick≥2+). Low socioeconomic status was defined by annual family income<$39,250 CAD, and receiving social assistance was based on government of Alberta health care insurance records. CVD, cerebrovascular disease; CHF, congestive heart failure; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.

  • a Mean (SD).

  • b Median (interquartile range).

  • c Among the 273,540 individuals with data available on medication use, 40,611 individuals had eGFR=15–59.9, 155,315 individuals had eGFR=60–89.9, and 77,614 individuals had eGFR≥90 ml/min per 1.73 m2.